Your fact-checks will appear here
Non-profit organization in the USA
Ultrasensitive PSA (uPSA) assays detect PSA at levels below 0.1 ng/mL — in some labs down to ~0.001–0.006 ng/mL — and so can identify biochemical recurrence earlier than standard assays, which typical...
After radical prostatectomy, the first PSA check is usually delayed until the immediate postoperative PSA has cleared (commonly 6–8 weeks), and major guideline frameworks recommend more frequent testi...
There is no credible clinical evidence in the provided sources that “horse paste” (ivermectin formulations intended for animals) is an established topical treatment for basal cell carcinoma (BCC). Maj...
No explicit, formal endorsements or dedicated recommendations for repurposed antiparasitic drugs appear in the recent guideline summaries and updates from the National Comprehensive Cancer Network (NC...
Three major prostate‑cancer guideline bodies—NCCN, AUA, and EAU—agree on the central role of serial PSA after radical prostatectomy but diverge on measurement sensitivity, timing of intervention, imag...
(Grade Group 4–5 or Gleason ≥8) with a deceptively low serum PSA should trigger more aggressive staging and consideration of treatment intensification rather than reassurance; modern imaging (includin...
defines (BCR) after radical as a postoperative prostate‑specific antigen (PSA) of ≥0.2 ng/mL confirmed by a second PSA ≥0.2 ng/mL, a threshold used to standardize reporting and guide consideration of ...
Ultrasensitive PSA (uPSA) assays lower analytical detection limits from the conventional ~0.1–0.2 ng/mL down to the 0.003–0.001 ng/mL range in some platforms; manufacturers and reviews report lower li...
There is no single universally agreed PSA cut‑off after radical prostatectomy that defines biochemical recurrence; many expert groups and major centres use two consecutive values ≥0.2 ng/mL as the pra...
(Kisqali) combined with an aromatase inhibitor—most commonly letrozole—has emerged as a standout first‑line (1L) combination therapy for hormone‑receptor–positive (HR+), HER2‑negative metastatic breas...
Three —, and —sit firmly as the standard first-line systemic option for HR‑positive, HER2‑negative advanced/metastatic breast cancer when combined with endocrine therapy, with guideline bodies and ran...
and tolerability profile is well characterized across randomized trials, meta-analyses and , and shows a distinct pattern—predominantly hematologic and hepatic risks with a known signal for QTc prolon...
, as tested in the program, is the only CDK4/6 inhibitor with consistent, statistically significant overall survival (OS) advantages reported across multiple phase III trials (MONALEESA‑2, ‑3, and ‑7)...
(ribociclib), a CDK4/6 inhibitor taken with endocrine therapy, improves key outcomes for people with ER‑positive, HER2‑negative metastatic breast cancer: randomized trials show meaningful increases in...
causes measurable bone injury through cell damage, vascular injury and altered remodeling that can produce focal insufficiency fractures and in cancer survivors . The strongest, actionable evidence su...
Biochemical recurrence that is suspected or imaged without a concomitant rise in standard PSA levels is unusual but documented, and management balances early salvage intent against risks of overtreatm...
The materials provided describe Pete Sulack as a proponent of faith‑infused functional medicine who promotes integrative protocols including orthomolecular support, hyperbaric oxygen, lifestyle change...
Major oncology guideline bodies (NCCN, ESMO, ASCO) have not adopted ivermectin as a recommended cancer treatment; available sources report only early-phase trials and preclinical work, with one active...
Dr. Pete Sulack promotes cancer approaches that mix repurposed antiparasitic drugs (ivermectin, mebendazole, fenbendazole), orthomolecular supplements, detoxification and faith-driven care; his site a...
There are no references to “macrophallia” or diagnostic thresholds for penile size in the provided urology sources; the search results instead concern hematuria, bladder and prostate cancer guidelines...